1
|
Ring OT, Hayter BR, Ronson TO, Agnew LR, Ashworth IW, Cherryman J, Gall MAY, Hamilton PR, Inglesby PA, Jones MF, Lamacraft AL, Leahy AJ, McKinney D, Miller-Potucka L, Powell L, Putra OD, Robbins AJ, Tomasi S, Wordsworth RA. Process Development, Manufacture, and Understanding of the Atropisomerism and Polymorphism of Verinurad. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00284] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Oliver T. Ring
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Barry R. Hayter
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Thomas O. Ronson
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Lauren R. Agnew
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Ian W. Ashworth
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Janette Cherryman
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Malcolm A. Y. Gall
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Peter R. Hamilton
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Phillip A. Inglesby
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Martin F. Jones
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Alex L. Lamacraft
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Adam J. Leahy
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - David McKinney
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Lucie Miller-Potucka
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Lyn Powell
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Okky D. Putra
- Early Product Development and Manufacturing, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden
| | - Andrew J. Robbins
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Simone Tomasi
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Rosemary A. Wordsworth
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| |
Collapse
|
2
|
Milovanović V, Petrović Z, Petrović V, Simijonović D, Mladenović M, Tomašević N, Čomić L, Radojević I. In vitro and in silico lipoxygenase inhibition studies and antimicrobial activity of pyrazolyl-phthalazine-diones. KRAGUJEVAC JOURNAL OF SCIENCE 2021. [DOI: 10.5937/kgjsci2143035m] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
The series of pyrazolyl-phthalazine-dione derivatives (PPDs) was subjected to evaluation of their in vitro lipoxygenase (LOX) inhibition and antimicrobial activities. Results obtained for LOX inhibition activities of PPDs showed that all compounds exhibit good to excellent activity, whereby compounds with eudesmic, syringic, vanillic or toluic moiety are the most active. Molecular modelling study was performed to investigate the possible mechanism of action and binding mode of compounds within the LOX active site. Docking results revealed that activity of the examined compounds depends on the functional group ability to create hydrogen bond accepting (HBA) and hydrophobic features (Hy) in the LOX-Ib active site. In addition, all substances were tested for their antibacterial and antifungal activities. The investigated compounds showed better antifungal than antibacterial activity. The highest antifungal activity was on Aspergillus fumigatus ATTC 204305 and Trichoderma viridae ATCC 13233.
Collapse
|
4
|
Ashworth IW, Campbell AD, Cherryman JH, Clark J, Crampton A, Eden-Rump EGB, Evans M, Jones MF, McKeever-Abbas S, Meadows RE, Skilling K, Whittaker DTE, Woodward RL, Inglesby PA. Process Development of a Suzuki Reaction Used in the Manufacture of Lanabecestat. Org Process Res Dev 2018. [DOI: 10.1021/acs.oprd.8b00312] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|